Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial

Abstract

Introduction: Oncologists have traditionally administered the maximum tolerated doses of drugs in chemotherapy. However, these toxicity-guided doses may lead to suboptimal efficacy. CURATE.AI is an indication-agnostic, mechanism-independent and efficacy-driven personalised dosing platform that may offer a more optimal solution. While CURATE.AI has already been applied in a variety of clinical settings, there are no prior randomised controlled trials (RCTs) on CURATE.AI-guided chemotherapy dosing for solid tumours. Therefore, we aim to assess the technical and logistical feasibility of a future RCT for CURATE.AI-guided solid tumour chemotherapy dosing. We will also collect exploratory data on efficacy and toxicity, which will inform RCT power calculations.Methods and analysis: This is an open-label, single-arm, two-centre, prospective pilot clinical trial, recruiting adults with metastatic solid tumours and raised baseline tumour marker levels who are planned for palliative-intent, capecitabine-based chemotherapy. As CURATE.AI is a small data platform, it will guide drug dosing for each participant based only on their own tumour marker levels and drug doses as input data. The primary outcome is the proportion of participants in whom CURATE.AI is successfully applied to provide efficacy-driven personalised dosing, as judged based on predefined considerations. Secondary outcomes include the timeliness of dose recommendations, participant and physician adherence to CURATE.AI-recommended doses, and the proportion of clinically significant dose changes. We aim to initially enrol 10 participants from two hospitals in Singapore, perform an interim analysis, and consider either cohort expansion or an RCT. Recruitment began in August 2020. This pilot clinical trial will provide key data for a future RCT of CURATE.AI-guided personalised dosing for precision oncology.Ethics and dissemination: The National Healthcare Group (NHG) Domain Specific Review Board has granted ethical approval for this study (DSRB 2020/00334). We will distribute our findings at scientific conferences and publish them in peer-reviewed journals.Trial registration number: NCT04522284

Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria

“…The drug interaction space can then be described by the coefficients arising from the equation and is represented in a smooth response surface. This correlation was first discovered by neural networks and subsequently, validated in multiple in vitro studies 16 , 25 - 37 and prospective human studies in infectious diseases, oncology, and many other indications 29 , 38 - 47 . This platform does not use synergy predictions, big data on pre-existing drug information, or in silico modeling.…”

The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens

“…Subsequent studies resolved this surface, which can rapidly identify optimal combinations, using a second-order algebraic function, with its coefficients determined through a small number of prospective experiments (Abdulla et al, 2020;Al-Shyoukh et al, 2011;Blasiak et al, 2021;Clemens et al, 2019;Ho, 2020;Ho et al, 2020;Lee et al, 2017;Lim et al, 2020;Mohd Abdul Rashid et al, 2015;Rashid et al, 2018;Silva et al, 2016;Wang et al, 2015;Wong et al, 2008). This correlation has subsequently been verified in prospective, human studies in infectious disease, cancer therapy, transplant medicine, and other indications (Tan BKJ et al, 2021;Blasiak et al, 2020;de Mel et al, 2020;Kee et al, 2019;Pantuck et al, 2018;Shen et al, 2020;Zarrinpar et al, 2016). IDentif.AI does not use pre-existing data for algorithm training, in silico modeling, or synergy prediction.…”

Discovery of Broad‐Spectrum Repurposed Drug Combinations Against Carbapenem‐Resistant Enterobacteriaceae (CRE) Through Artificial Intelligence (AI)‐Driven Platform

“…[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] The second order quadratic relationship was also confirmed via prospective human studies. [31][32][33][34][35][36][37] This platform is mechanism agnostic and does not rely on pre-existing data or in silico modeling. All results from IDentif.AI are based on prospectively obtained experimental data, and pinpointed combinations are optimal within the selected pool of drugs.…”